简介：摘要目的对肺表面活性物质应用于新生儿呼吸窘迫综合症的实际价值以及临床疗效进行探讨.方法回顾分析２０１４年１月－２０１５年１月我院新生儿监护病房中５４例患有呼吸窘迫综合征的早产儿,其胎龄均小于３５周.随机将５４例早产婴儿随机分为实验组与对照组实验组２７例患者应用肺表面活性物质,对照组２７例患者不应用肺表面活性物质,将两组的临床疗效进行探讨比较.结果实验组患儿并发症中发生１例脑室内出血,２例支气管发育不良,２例患有视网膜病,１例死亡,好转２１例,患儿住院天数为(１０．５±１４．０)天.对照组患儿并发症中,发生４例脑室内出血,２例支气管发育不良,５例患有视网膜病,１０例死亡,好转６例,患儿住院天数为(２１．５±１２．０)天.经过比较实验组与对照组脑室内出血、视网膜病情况以及住院天数具有显著差异(P＜０．０５),但是支气管发育不良没有显著差异(P＞０．０５).结论对出现呼吸窘迫综合症的新生儿应该及早监护,应用肺表面活性物质,可以有效降低并发症发生,提高临床疗效.关键词新生儿呼吸窘迫综合征;肺表面活性物质;临床疗效ThevalueofapplyingtheactivitymaterialofpulmonarysurfacetoNeonatalRespiratoryDistressSyndromeAbstractObjectiveToinvestigatetheefficiencyofpulmonarysurfactant(PS)thetherapyforprematureinfantsinlocalhospitalsbeforeneonataltransportation．MethodsIn２０１２January－２０１３Januaryinourhospitalneonatalintensivecareunitin５４prematureinfantswithrespiratorydistresssyndrome,whichwerelessthan３５weeksofgestationalage．Atotalof５４casesofprematureinfantswererandomlydividedintoexperimentalgroupandcontrolgroupexperimentalgroupof２７patientsofpulＧmonarysurfactant,acontrolgroupof２７patientswithoutpulmonarysurfactant．Comparedanddiscussedtheclinicalcurativeeffectofthetwogroups．ResultsIntheexperiＧmental,１casesofhemorrhage,including２casesofbronchialdysplasia,２patientswithretinopathy,１casesofdeath,hospitalizationforchildren(１０．５±１４)days．TheconＧtrolgroupwerecomplications,including４casesofhemorrhage,２casesofbronchialdysplasia,５patientswithretinopathy,１０casesofdeath,hospitalizationforchildren(２１．５±１２)days．ConclusionsPScombinedwithmechanicalventilationisaeffectiveandrapidwaytotreatNRDS．PScombinedwithmechanicalventilationcanimprovetheprognoKsiesyowfotrhdesnewbornwithNRDS．Neonatalrespiratorydistresssyndrome;Pulmonarysurfactant;Clinicaleffect中图分类号R４７３．７文献标识码B文章编号１００８－６３１５(２０１５)１０－０３４７－０２